Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Early Phase 1

4(50.0%)

Phase 1

3(37.5%)

Phase 2

1(12.5%)

8Total

Early Phase 1(4)

Phase 1(3)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07087158Phase 2Not Yet Recruiting

A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma

Role: lead

NCT07073833Phase 1Recruiting

The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma

Role: lead

NCT06234904Phase 1Unknown

Study of IBR733 Cell Injection in Acute Myeloid Leukemia

Role: lead

NCT06001684Phase 1Unknown

Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors

Role: lead

NCT05137275Early Phase 1Unknown

Study of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors

Role: collaborator

NCT05411757Early Phase 1Unknown

IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer

Role: collaborator

NCT05194709Early Phase 1Unknown

Study of Anti-5T4 CAR-NK Cell Therapy in Advanced Solid Tumors

Role: collaborator

NCT05215015Early Phase 1Unknown

Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia

Role: collaborator

All 8 trials loaded